For decades, the "prior authorization" process—a utilization management tool used by health insurers to determine if a prescribed procedure, service, or medication is medically necessary—has been a source of significant friction between providers and payers. While insurers argue these checks prevent unnecessary spending and ensure patient safety, providers frequently characterize them as administrative hurdles that delay critical care and contribute to clinician burnout.
A new, comprehensive analysis from KFF (formerly the Kaiser Family Foundation) has finally pulled back the curtain on these practices. By examining data from 14 major insurers covering 71 million enrollees across Medicare Advantage, Medicaid managed care, and the ACA Marketplace, the report offers the most detailed snapshot to date of how often requests are denied and how frequently those decisions are reversed. Yet, despite this newfound transparency, the report reveals that the health insurance landscape remains opaque, fragmented, and difficult for the average patient to navigate.
Main Facts: The Scope of Denials
The 2025 data paints a clear picture of an industry that relies heavily on automated and manual utilization reviews. Across the three primary insurance sectors, the denial rates for standard prior authorization requests are significant:
- ACA Marketplace: 18% denial rate.
- Medicaid Managed Care: 14% denial rate.
- Medicare Advantage: 12% denial rate.
These figures represent millions of individual instances where a patient’s initial request for care was blocked by their insurer. While the median response time for standard requests hovers around one day—suggesting that the process is relatively fast—the sheer volume of denials suggests a systemic barrier to care that transcends mere administrative efficiency.
Expedited requests, typically reserved for urgent clinical scenarios, saw slightly lower denial rates, with median response times of approximately half a day for Medicare Advantage and one full day for Medicaid and ACA plans. While these turnaround times may seem impressive on paper, they do not account for the clinical consequences that occur during the waiting period.
Chronology: From Regulatory Mandates to Public Disclosure
The KFF analysis arrives on the heels of a landmark 2024 final rule issued by the Centers for Medicare & Medicaid Services (CMS). This regulation was designed to force a cultural shift toward transparency, requiring payers to publicly disclose their prior authorization metrics—including approval and denial rates—directly on their websites.
The Regulatory Push (2023–2024)
The CMS mandate was a response to mounting pressure from provider groups, such as the American Medical Association (AMA), which had long argued that insurers were using prior authorization as a "black box" to manage costs at the expense of patient health. The 2024 rule aimed to standardize this process, forcing insurers to provide a rationale for their utilization management strategies.
The Implementation Phase (2025)
As 2025 progressed, insurers began publishing these metrics. However, the resulting data dump revealed a major flaw in the regulatory approach: while the rates were disclosed, the reasons were not. The public can now see that a specific insurer might deny 20% of requests, but they cannot see if those denials are for high-cost surgical procedures, expensive specialty drugs, or routine diagnostic imaging.
The Ongoing Skepticism (2026 and Beyond)
Last year, major insurers made high-profile commitments to "streamline" prior authorization, promising to adopt electronic, automated standards and improve the transparency of their determinations. Despite these promises, recent surveys suggest that the physician community remains deeply skeptical. Many providers argue that these commitments are largely performative, failing to address the fundamental issue: the clinical appropriateness of the denials themselves.
Supporting Data: Variance Across the Industry
One of the most striking findings in the KFF report is the massive disparity in denial rates between different insurance providers, even within the same market segment. This variance suggests that there is no industry-wide "standard" for what constitutes a medically necessary service.
Medicare Advantage
- Lowest Denial Rate: Elevance (5%)
- Highest Denial Rate: UnitedHealth Group (17%)
Medicaid Managed Care
- Lowest Denial Rate: L.A. Care Health Plan (2%)
- Highest Denial Rate: Independence Health Group (23%)
ACA Marketplace
- Lowest Denial Rate: GuideWell (3%)
- Highest Denial Rate: Centene (25%)
The fact that an enrollee could face a 3% denial rate with one insurer and a 25% denial rate with another for the same medical service suggests that where a patient lives and which insurance plan they hold has a direct, measurable impact on their access to care.
The "Appeal" Paradox
Perhaps the most damning statistic in the report relates to the appeals process. If prior authorization is intended to ensure medical necessity, one would assume that the initial denial rate is highly accurate. However, the data proves otherwise:
- Medicare Advantage: 67% of appealed denials are overturned.
- Medicaid Managed Care: 47% of appealed denials are overturned.
- ACA Marketplace: 43% of appealed denials are overturned.
When an insurer’s decision is challenged, the fact that nearly half—or in the case of Medicare Advantage, more than two-thirds—of those decisions are reversed suggests that the initial denial was likely incorrect. Furthermore, the report notes that denials are rarely appealed, meaning that for every overturned denial, there are likely thousands of patients who accept the denial as final, potentially missing out on necessary medical treatment.
Official Responses and Perspectives
The KFF analysis has sparked a wave of discourse among stakeholders.
The Patient and Provider Perspective
Advocacy groups and provider organizations have lauded the increased data availability but remain frustrated by the lack of context. "Knowing that a company denies one in five claims doesn’t help a patient choose a plan if they don’t know what kind of care is being denied," said one health policy analyst familiar with the study. Providers argue that the administrative burden of filing appeals—and the time required to do so—is a deterrent that keeps many patients from seeking the care they are entitled to.
The Insurer Perspective
Insurers continue to maintain that prior authorization is a vital tool for cost containment and the prevention of "over-utilization." In their public statements regarding the 2026 commitments, industry representatives emphasized that they are moving toward "gold-carding" programs—where providers with high approval rates receive fewer, or no, prior authorization requirements—and electronic, automated processing that will speed up decision-making.
Implications: The Transparency Gap
While the CMS 2024 rule was a victory for transparency, the KFF analysis highlights that "data" does not equal "information." The current state of disclosure poses three major challenges:
1. The Interpretation Hurdle
Health insurance terminology is notoriously difficult for the average consumer to grasp. Without clear, standardized reporting, the average patient cannot use these metrics to make an informed choice during open enrollment. The data is currently buried in corporate disclosures rather than being presented in a way that helps a patient understand, "If I have this chronic condition, which insurer is more likely to cover my medication?"
2. Lack of Standardization
Insurers are not required to report this data in a uniform format. This makes cross-plan comparison an exercise in data science rather than a simple consumer review. As KFF noted, the target audience of these reports—the patient—is currently the least equipped to understand them.
3. The Future of Advocacy
The future of this issue likely lies in the hands of "intermediaries"—third-party organizations, researchers, and consumer advocacy groups that can aggregate, clean, and translate these complex datasets into actionable tools. Until then, the "transparency" offered by the 2024 rule remains a theoretical benefit rather than a practical one.
Conclusion
The KFF report makes it clear that while the conversation around prior authorization has shifted from "secrecy" to "disclosure," the path toward true patient-centered care is still obstructed. The high rate of overturned appeals serves as a critical warning that current utilization management practices are far from perfect. As the healthcare industry moves into the latter half of the decade, the focus must shift from simply reporting denial rates to evaluating the clinical outcomes of those denials. Only when patients, providers, and regulators can see the what and why behind every denial will the promise of true transparency be realized.
